HUTCHMED (NASDAQ:HCM) Shares Gap Down – Here’s What Happened

HUTCHMED (China) Limited (NASDAQ:HCM)’s stock price gapped down before the market opened on Thursday . The stock had previously closed at $14.18, but opened at $13.70. HUTCHMED shares last traded at $13.37, with a volume of 40,432 shares traded.

Analyst Ratings Changes

Separately, StockNews.com cut shares of HUTCHMED from a “buy” rating to a “hold” rating in a research note on Monday, November 18th.

HUTCHMED Stock Down 0.3 %

The company has a 50-day moving average of $15.56 and a 200 day moving average of $17.53. The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07.

Institutional Investors Weigh In On HUTCHMED

A number of hedge funds have recently made changes to their positions in the company. Blue Trust Inc. increased its holdings in shares of HUTCHMED by 99.9% during the fourth quarter. Blue Trust Inc. now owns 7,068 shares of the company’s stock worth $102,000 after buying an additional 3,532 shares in the last quarter. Crossmark Global Holdings Inc. increased its holdings in HUTCHMED by 10.7% during the 4th quarter. Crossmark Global Holdings Inc. now owns 18,591 shares of the company’s stock valued at $268,000 after purchasing an additional 1,799 shares in the last quarter. Public Employees Retirement System of Ohio bought a new position in HUTCHMED in the 3rd quarter valued at $35,000. Jane Street Group LLC boosted its stake in HUTCHMED by 362.2% in the third quarter. Jane Street Group LLC now owns 62,997 shares of the company’s stock worth $1,305,000 after purchasing an additional 49,366 shares in the last quarter. Finally, State Street Corp grew its holdings in shares of HUTCHMED by 0.9% during the third quarter. State Street Corp now owns 349,524 shares of the company’s stock worth $6,826,000 after purchasing an additional 3,078 shares during the last quarter. Institutional investors and hedge funds own 8.82% of the company’s stock.

HUTCHMED Company Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.